Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic

Best Pharmaceutical Stocks to Buy Now (2022)

Top pharmaceutical stocks in 2022 ranked by overall Zen Score. See the best pharmaceutical stocks to buy now, according to analyst forecasts for the drug manufacturers - specialty & generic industry.

According to Zen Score, the 3 best pharma stocks to buy right now are:

IRONWOOD PHARMACEUTICALS (NASDAQ:IRWD) is the top pharmaceutical stock with a Zen Score of 56, which is 27 points higher than the pharmaceutical industry average of 29. It passed 18 out of 33 due diligence checks and has strong fundamentals. IRONWOOD PHARMACEUTICALS has seen its stock lose -9.56% over the past year, overperforming other pharmaceutical stocks by 30 percentage points.

IRONWOOD PHARMACEUTICALS has an average 1 year price target of $14.00, an upside of 26.47% from IRONWOOD PHARMACEUTICALS's current stock price of $11.07.

IRONWOOD PHARMACEUTICALS stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering IRONWOOD PHARMACEUTICALS, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

ORGANOGENESIS HOLDINGS (NASDAQ:ORGO) is the second best pharmaceutical stock with a Zen Score of 55, which is 26 points higher than the pharmaceutical industry average of 29. It passed 18 out of 33 due diligence checks and has strong fundamentals. ORGANOGENESIS HOLDINGS has seen its stock lose -67.25% over the past year, underperforming other pharmaceutical stocks by -28 percentage points.

ORGANOGENESIS HOLDINGS has an average 1 year price target of $22.50, an upside of 298.94% from ORGANOGENESIS HOLDINGS's current stock price of $5.64.

ORGANOGENESIS HOLDINGS stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering ORGANOGENESIS HOLDINGS, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

COLLEGIUM PHARMACEUTICAL (NASDAQ:COLL) is the third best pharmaceutical stock with a Zen Score of 54, which is 25 points higher than the pharmaceutical industry average of 29. It passed 18 out of 33 due diligence checks and has strong fundamentals. COLLEGIUM PHARMACEUTICAL has seen its stock lose -36.83% over the past year, overperforming other pharmaceutical stocks by 3 percentage points.

COLLEGIUM PHARMACEUTICAL has an average 1 year price target of $32.25, an upside of 108.2% from COLLEGIUM PHARMACEUTICAL's current stock price of $15.49.

COLLEGIUM PHARMACEUTICAL stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering COLLEGIUM PHARMACEUTICAL, 25% have issued a Strong Buy rating, 50% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

VIATRIS (NASDAQ:VTRS) has an annual dividend yield of 3.99%, which is 2 percentage points higher than the pharmaceutical industry average of 2.44%. VIATRIS's dividend payout is stable, having never dropped by more than 10% in the last 10 years. VIATRIS's dividend has shown consistent growth over the last 10 years.

VIATRIS's dividend payout ratio of 321.4% indicates that its dividend yield might not be sustainable for the long-term.

PROPHASE LABS (NASDAQ:PRPH) has an annual dividend yield of 3.59%, which is 1 percentage points higher than the pharmaceutical industry average of 2.44%.

PROPHASE LABS's dividend payout ratio of 51.7% indicates that its dividend yield is sustainable for the long-term.

PHIBRO ANIMAL HEALTH (NASDAQ:PAHC) has an annual dividend yield of 2.59%, which is the same as the pharmaceutical industry average of 2.44%. PHIBRO ANIMAL HEALTH's dividend payout is stable, having never dropped by more than 10% in the last 10 years. PHIBRO ANIMAL HEALTH's dividend has shown consistent growth over the last 10 years.

PHIBRO ANIMAL HEALTH's dividend payout ratio of 33.1% indicates that its dividend yield is sustainable for the long-term.

Pharmaceutical stocks were down -2.38% in the last day, and down -4.54% over the last week.

We couldn't find a catalyst for why pharmaceutical stocks are down.

Based on WallStreetZen's Valuation Score, the 3 most undervalued pharmaceutical stocks right now are:

COLLEGIUM PHARMACEUTICAL (NASDAQ:COLL) is the most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. COLLEGIUM PHARMACEUTICAL has a valuation score of 71, which is 42 points higher than the pharmaceutical industry average of 29. It passed 5 out of 7 valuation due diligence checks.

COLLEGIUM PHARMACEUTICAL's stock has dropped -36.83% in the past year. It has overperformed other stocks in the pharmaceutical industry by 3 percentage points.

SUPERNUS PHARMACEUTICALS (NASDAQ:SUPN) is the second most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. SUPERNUS PHARMACEUTICALS has a valuation score of 71, which is 42 points higher than the pharmaceutical industry average of 29. It passed 5 out of 7 valuation due diligence checks.

SUPERNUS PHARMACEUTICALS's stock has dropped -10.96% in the past year. It has overperformed other stocks in the pharmaceutical industry by 29 percentage points.

PHIBRO ANIMAL HEALTH (NASDAQ:PAHC) is the third most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. PHIBRO ANIMAL HEALTH has a valuation score of 57, which is 28 points higher than the pharmaceutical industry average of 29. It passed 4 out of 7 valuation due diligence checks.

PHIBRO ANIMAL HEALTH's stock has dropped -34.49% in the past year. It has overperformed other stocks in the pharmaceutical industry by 5 percentage points.